MitoQ
Company
MitoQ develops 14 assets, the furthest in phase 2 (mitoq in chronic hepatitis c). Mostly supplement and small molecule acting on Oxidative stress and ROS signalling.
- 14
- Assets
- Furthest stage
- Phase 2
- 0
- Trials
- 0
- Signals
Pipeline
14Positively charged antioxidant accumulates in mitochondria to neutralize free radicals and oxidative stress.
Phase 2, Small molecule, Oxidative stress and ROS signalling, chronic hepatitis c, non-alcoholic fatty liver disease
Stage not known, Supplement
Stage not known, Supplement
11 more assets
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials3
- People4
- Similar companies6